Amgen Inc (AMGN · NASDAQ)

AMGN · MARKET VIEW

Market view · as of Jul 27, 2026

Revenue (TTM)
$37.22B
+5.8% YoY
Gross margin
71.4%
EPS (latest q)
$5.15
vs $4.77 est · beat
52-wk position
92.4%
-2.4% vs 52w high · +6.6% 1mo

Price (last ~year)

Amgen Inc. (AMGN) reported first-quarter 2026 revenue of $8.62 billion, marking four consecutive quarters of earnings beats. The biopharmaceutical company, which maintains a market capitalization of $202.95 billion, recorded trailing twelve-month revenue of $37.22 billion and an operating margin of 33.8%. Shares are currently priced at $376.04, reflecting an 11.6% gain over the last three months, while the firm carries $57.32 billion in total debt with a debt-to-EBITDA ratio of 3.4x.

Valuation

Market cap
$202.95B
P/E
26.19
PEG
2.061
P/B
22.08
P/S
5.45
EV/EBITDA
14.89
Beta
0.403
Analyst target
$356.69

Quality & returns

Gross margin
71.4%
Operating margin
33.8%
Profit margin
21.0%
ROE
101.3%
ROA
8.3%

Price movement

Last
$376.04
1-month
+6.6%
3-month
+11.6%
RSI (14)
60
vs SMA200
+11.2%
52-wk position
92.4% -2.4% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$8.62B$2.67B$1.82B$3.86B
2025-12-31$9.90B$3.94B$1.33B$3.30B
2025-09-30$9.56B$2.53B$3.22B$5.91B
2025-06-30$9.17B$2.64B$1.43B$3.62B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots